+91-8668442535

Chemotherapy Induced Nausea And Vomiting Treatment Market By Drug Class (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine, Others) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Industry Outlook

The chemotherapy induced nausea and vomiting treatment market is set to reach US$ 3,626.1 Mn by 2026 from US$ 2,057.4 Mn in 2017 showcasing progressive growth at a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2018 to 2026. As per the latest statistics provided by the National Cancer Institute in 2018 approximately 1,735,350 new cancer cases will be reported with an estimation of 609,640 people dying with cancer. Technological advancement in the diagnostic kits have resulted in early cancer diagnosis which helps the physician to enroll the patient on chemotherapy treatment immediately. It is important to understand that 90% patient receiving chemotherapy suffer with nausea and vomiting.

There has been a shift in the treatment regimen, earlier dopamine antagonist in combination with corticosteroid were prescribed as antiemetic agents, which have been replaced by drug combination of serotonin receptor antagonist and NK1 receptor antagonist. Rising prevalence of cancer and growing popularity of chemotherapy as treatment option is responsible for the dominance of North America in CINV treatment market. Developing healthcare infrastructure and competition exerted by local generic drug manufacturers stimulate the CINV market growth in Asia Pacific.

Market Synopsis

Chemotherapy Induced Nausea And Vomiting Treatment Market

Get a sample copy for more information

Excellent pharmacokinetic properties to boost the sale of NK1 receptor antagonist during the forecast period

Serotonin receptor antagonist are leading the drug class market for chemotherapy induced nausea and vomiting treatment on account of its excellent antiemetic activity in cancer patients suffering with acute nausea. Drugs such as palonosetron, granisetron and dolasetron are available as oral, parenteral and transdermal patches, catering the need of patients belonging to all age groups. Multiple studies conducted in the clinical trials have suggested the combined therapy of dopamine antagonist with benzodiazepine or corticosteroid to be effective in treating the patients suffering with refractory CINV. NK1 receptor antagonist have shown excellent clinical outcomes in the treatment of delayed nausea with outstanding pharmacokinetic properties. They are prescribed in combination with 5HT3 receptor antagonist e.g. Alkynzeo (Helsinn Healthcare) and is set to register tremendous growth during the forecast period.

Chemotherapy Induced Nausea And Vomiting Treatment Market

Get a sample copy for more information

Increasing number of patients seeking chemotherapy to drive the CINV treatment market in North America

North America is currently leading the chemotherapy induced nausea and vomiting treatment market with 38% regional share. Rising prevalence of patients suffering with cancer, growing popularity of chemotherapy as treatment option among the patient population drives the CINV market in North America. Major players such as Sanofi-Aventis and Helsinn healthcare are striving to manufacture effective antiemetic drugs to treat CINV in North America. Existence of well-developed healthcare infrastructure, and adherence to treatment guidelines steers the CINV market in Europe. Competition exerted by the local players manufacturing generic drugs and supportive regulatory environment propel the CINV market growth in Asia Pacific region. Latin America and Middle East and Africa serve as lucrative market due to rising awareness of chemotherapy induced nausea and vomiting in healthcare professionals and rise in per capita income.

Chemotherapy Induced Nausea And Vomiting Treatment Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Quantitative analysis for the report chemotherapy induced nausea and vomiting treatment market is postulated on the basis of latest market trends. The market is further segmented as drug class and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Drug Class (2016–2026; US$ Mn)
 • Serotonin Receptor Antagonist
   o Ondansetron
   o Granisetron
   o Dolasetron
   o Palonosetron
 • Neurokinin NK1 Receptor Antagonist
   o Aprepitant
   o Casopitant
   o Netupitant
 • Dopamine Antagonist
   o Metoclopramide
   o Prochlorperazine
 • Benzodiazepine
   o Lorazepam\
   o Others (Corticosteroids, Cannabinoids)

 Geography Segment (2016–2026; US$ Mn)
 • North America (United States and Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Latest market trends and quantitative analysis are performed to understand the market dynamics existing in the chemotherapy induced nausea and vomiting treatment market. Vital information regarding the inorganic business strategies such as mergers and collaboration between pharmaceutical players are highlighted in this report. In the product portfolio section quick insight regarding the diverse brands in different drug combinations is obtained. The major players dominating the chemotherapy induced nausea and vomiting treatment market are Baxter Pharmaceuticals, Eisai, Inc., Helsinn Healthcare, GlaxoSmithkline, Plc, Merck & Co. Inc., ProStrakan, Inc., Pfizer, Inc., Sanofi-Aventis, Solvay Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report

  • Who are the leading players in the chemotherapy induced nausea and vomiting treatment market?
  • What will be the performance of the CINV market during the forecast period from 2018 to 2026?
  • What are the latest market trends existing in the CINV treatment market?
  • What are the drivers and challenges faced by the CINV treatment market?
  • What is the pathophysiology that triggers the chemotherapy induced nausea and vomiting?
  • What are the treatment guidelines adopted by the healthcare professionals throughout the globe?
  • Which is the leading and fastest growing drug class segment for CINV treatment market?
  • Which is the leading and fastest growing regional segment for CINV treatment market?
Choose License Type
Trusted By
Godaddy
Related Report










Published Date:  Aug 2018
Category:  Pharmaceuticals
Report ID:   59261
Report Format:   PDF
Pages:   120
Rating:    4.3 (55)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support